| Pharmaceutical Information |
| Drug Name |
Bosutinib |
| Drug ID |
BADD_D00286 |
| Description |
Bosutinib is a Bcr-Abl kinase inhibitor for the treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Compared to other tyrosine kinase inhibitors, it has a more favourable hematologic toxicity profile. FDA approved on September 4, 2012. |
| Indications and Usage |
Treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy in adult patients. |
| Marketing Status |
Not Available |
| ATC Code |
L01EA04 |
| DrugBank ID |
DB06616
|
| KEGG ID |
D03252
|
| MeSH ID |
C471992
|
| PubChem ID |
5328940
|
| TTD Drug ID |
D0OB0F
|
| NDC Product Code |
54893-0042; 54893-0048; 54893-0041; 46708-878 |
| Synonyms |
bosutinib | SKI606 | SKI-606 |
|
| Chemical Information |
| Molecular Formula |
C26H29Cl2N5O3 |
| CAS Registry Number |
380843-75-4 |
| SMILES |
CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
